{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T05:06:23Z","timestamp":1779512783354,"version":"3.53.1"},"reference-count":118,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008725","name":"Maj Institute of Pharmacology, Polish Academy of Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The effects of antidepressants on limbic structures, important in the context of the treatment of Parkinson\u2019s disease (PD)-associated depression, are relatively poorly explored in animal models. The present study investigated the impact of the tricyclic antidepressant amitriptyline (AMI), administered chronically alone or in combination with L-DOPA, on anhedonia, monoamine levels, and the binding of radioligands to their transporters in the limbic structures of unilaterally 6-OHDA-lesioned rats. Anhedonia, as a core symptom of depression, was evaluated using the sucrose preference test. Tissue concentrations of noradrenaline (NA), dopamine (DA) and serotonin (5-HT) and their metabolites in the prefrontal cortex (PFC) and hippocampus (HIP) were assayed by HPLC method. Bindings of [3H]nisoxetine to noradrenaline transporter (NET), [3H]GBR 12,935 to dopamine transporter (DAT), and [3H]citalopram to serotonin transporter (SERT) in the nucleus accumbens (NAcc), PFC, and HIP were analyzed by autoradiography. Three weeks of treatment of unilaterally 6-OHDA-lesioned rats with AMI alone significantly reduced the intake of sucrose solution compared to the sham-operated control, but the combined administration of AMI+L-DOPA enhanced sucrose consumption. Administration of AMI+L-DOPA increased tissue DA concentrations in the lesioned and intact PFC and HIP more distinctly than L-DOPA alone. L-DOPA alone significantly decreased tissue 5-HT content in the lesioned PFC and HIP, while the addition of AMI reversed this effect. 6-OHDA administered unilaterally into the MFB drastically decreased DAT binding in the lesioned NAcc while increasing it on the intact side. Neither AMI nor L-DOPA, given alone or jointly, affected DAT binding in the lesioned NAcc. SERT binding was significantly reduced in the PFC, NAcc and HIP on both sides of the brain in the AMI- or AMI+L-DOPA-treated groups. NET binding decreased in the PFC and NAcc in the AMI-treated group, but no such effect was observed in the AMI+L-DOPA-treated group. The obtained results are discussed in relation to the impaired psychiatric functions in PD.<\/jats:p>","DOI":"10.3390\/biom16050743","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:07:47Z","timestamp":1779444467000},"page":"743","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interactions of the Tricyclic Antidepressant Drug Amitriptyline with L-DOPA in the Nucleus Accumbens, Prefrontal Cortex and Hippocampus of Unilaterally 6-OHDA-Lesioned Rats: Relevance to Depression in Parkinson\u2019s Disease"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1359-8860","authenticated-orcid":false,"given":"Kinga","family":"Kami\u0144ska","sequence":"first","affiliation":[{"name":"Maj Institute of Pharmacology, Polish Academy of Sciences, Sm\u0119tna Street 12, 31-343 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4800-6511","authenticated-orcid":false,"given":"Tomasz","family":"Lenda","sequence":"additional","affiliation":[{"name":"Maj Institute of Pharmacology, Polish Academy of Sciences, Sm\u0119tna Street 12, 31-343 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Konieczny","sequence":"additional","affiliation":[{"name":"Maj Institute of Pharmacology, Polish Academy of Sciences, Sm\u0119tna Street 12, 31-343 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9970-8548","authenticated-orcid":false,"given":"El\u017cbieta","family":"Lorenc-Koci","sequence":"additional","affiliation":[{"name":"Maj Institute of Pharmacology, Polish Academy of Sciences, Sm\u0119tna Street 12, 31-343 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson\u2019s disease: Clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1155\/2006\/138263","article-title":"Neuropharmacological treatment of mental dysfunction in Parkinson\u2019s disease","volume":"17","author":"McNamara","year":"2006","journal-title":"Behav. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jagp.2019.03.002","article-title":"The neuropsychiatry of Parkinson disease: A perfect storm","volume":"27","author":"Weintraub","year":"2019","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Usigli, H.A., Ortiz, G.G., Charles-Ni\u00f1o, C., Mireles-Ram\u00edrez, M.A., Pacheco-Mois\u00e9s, F.P., Torres-Mendoza, B.M.G., Hern\u00e1ndez-Cruz, J.J., Delgado-Lara, D.L.d., and Ram\u00edrez-Jirano, L.J. (2023). Neurocognitive psychiatric and neuropsychological alterations in Parkinson\u2019s disease: A basic and clinical approach. Brain Sci., 13.","DOI":"10.3390\/brainsci13030508"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson\u2019s disease: Diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1468-1331.2008.02056.x","article-title":"Non-motor symptoms in Parkinson\u2019s disease","volume":"15","author":"Poewe","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson\u2019s disease: Dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_8","first-page":"659","article-title":"Neuropsychiatric symptoms in Parkinson\u2019s disease","volume":"5","author":"Aarsland","year":"2015","journal-title":"J. Park. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Cattaneo, C., Fabbrini, A., Belvisi, D., Aiello, F., Marchet, F., and Fabbrini, G. (2025). Non-motor symptoms: The hidden face of Parkinson\u2019s Disease. Cells, 15.","DOI":"10.20944\/preprints202511.0689.v1"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cne.902870308","article-title":"Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson\u2019s disease with and without dementia and depression","volume":"287","author":"Asan","year":"1989","journal-title":"J. Comp. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","article-title":"Loss of brainstem serotonin- and substance P-containing neurons in Parkinson\u2019s disease","volume":"51","author":"Halliday","year":"1990","journal-title":"Brain Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ana.410270405","article-title":"Neuropathology of immunohistochemically identified brainstem neurons in Parkinson\u2019s disease","volume":"27","author":"Halliday","year":"1990","journal-title":"Ann. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00005072-199111000-00006","article-title":"The neuropathologic basis of different clinical subgroups of Parkinson\u2019s disease","volume":"50","author":"Paulus","year":"1991","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","article-title":"Stages in the development of Parkinson\u2019s disease-related pathology","volume":"318","author":"Braak","year":"2004","journal-title":"Cell Tissue Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jnnp.2006.098327","article-title":"A multicentre longitudinal observational study of changes in self-reported health status in people with Parkinson\u2019s disease left untreated at diagnosis","volume":"78","author":"Grosset","year":"2007","journal-title":"J. Neurol. Nuerosurg. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/mds.21586","article-title":"Prevalence of nonmotor symptoms in Parkinson\u2019s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients","volume":"22","author":"Schapira","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1002\/ana.21472","article-title":"Nonmotor manifestations of Parkinson\u2019s disease","volume":"64","author":"Simuni","year":"2008","journal-title":"Ann. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0006-3223(03)00530-4","article-title":"Prevalence, etiology, and treatment of depression in Parkinson\u2019s disease","volume":"54","author":"McDonald","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/mds.21376","article-title":"Depression symptoms in movement disorders: Comparing Parkinson\u2019s disease, dystonia, and essential tremor","volume":"22","author":"Miller","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1468-1331.2008.02058.x","article-title":"Depressive symptoms in Parkinson\u2019s disease","volume":"15","author":"Lemke","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/mds.22589","article-title":"Neuropsychiatric symptoms in Parkinson\u2019s disease","volume":"24","author":"Aarsland","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0891988709351833","article-title":"Occurrence risk and structure of depression in Parkinson disease with and without dementia: Results from GEPAD study","volume":"23","author":"Riedel","year":"2010","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00415-010-5465-z","article-title":"Frequency of dementia, depression, and other neuropsychiatric symptoms in 1449 outpatients with Parkinson\u2019s disease","volume":"257","author":"Riedel","year":"2010","journal-title":"J. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2010.03325.x","article-title":"Treatment of depressive symptoms in Parkinson\u2019s disease","volume":"18","author":"Barone","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/0891988704267456","article-title":"Depression in Parkinson\u2019s disease: Conceptual issues and clinical challenges","volume":"17","author":"Leentjens","year":"2004","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson\u2019s disease","volume":"23","author":"Reijnders","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Decourt, M., Jim\u00e9nez-Urbieta, H., Benoit-Marand, M., and Fernagut, P.-O. (2021). Neuropsychiatric and cognitive deficits in Parkinson\u2019s disease and their modeling in rodents. Biomedicines, 9.","DOI":"10.3390\/biomedicines9060684"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1136\/jnnp.74.9.1308","article-title":"Physical anhedonia in Parkinson\u2019s disease","volume":"74","author":"Isella","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1176\/appi.neuropsych.11110332","article-title":"Anhedonia in Parkinson\u2019s disease: An overview","volume":"24","author":"Loas","year":"2012","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jns.2016.10.051","article-title":"Young Japanese Expert Group for Parkinson\u2019s Disease and Movement Disorders: YJ-EXPANDS. Anhedonia and its correlation with clinical aspects in Parkinson\u2019s disease","volume":"372","author":"Nagayama","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"110289","DOI":"10.1016\/j.pnpbp.2021.110289","article-title":"Anhedonia as a central factor in depression: Neural mechanisms revealed from preclinical to clinical evidence","volume":"110","author":"Wang","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-2007-1014317","article-title":"Anhedonia in schizophrenic, depressed, or alcohol-dependent patients\u2014Neurobiological correlates","volume":"27","author":"Heinz","year":"1994","journal-title":"Pharmacopsychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/brain\/awh445","article-title":"Depression in Parkinson\u2019s disease: Loss of dopamine and noradrenaline innervation in the limbic system","volume":"128","author":"Remy","year":"2005","journal-title":"Brain"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/BF01487648","article-title":"Distribution of 5-hydroxytryptamine (serotonin) in the human brain and its behavior in patients with Parkinson\u2019s syndrome","volume":"39","author":"Bernheimer","year":"1961","journal-title":"Klin. Wochenschr."},{"key":"ref_36","first-page":"120","article-title":"Preferential loss of serotonin markers in caudate versus putamen in Parkinson\u2019s disease","volume":"131","author":"Kish","year":"2008","journal-title":"Brain"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0006-8993(94)91761-2","article-title":"Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: Observations in Parkinson\u2019s disease and normal subjects","volume":"639","author":"Shannak","year":"1994","journal-title":"Brain Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.410220207","article-title":"Aminergic systems in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"22","author":"Zweig","year":"1987","journal-title":"Ann. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0006-8993(83)90993-9","article-title":"Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson\u2019s disease","volume":"275","author":"Scatton","year":"1983","journal-title":"Brain Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.pharep.2017.05.016","article-title":"Depressive-like neurochemical and behavioral markers of Parkinson\u2019s disease after 6-OHDA administered unilaterally to the rat medial forebrain bundle","volume":"69","author":"Lenda","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments","volume":"50","author":"Schwarting","year":"1996","journal-title":"Prog. Neurobiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e70008","DOI":"10.1111\/jnc.70008","article-title":"Challenges and opportunities in exploring non-motor symptoms in 6-hydroxydopamine models of Parkinson\u2019s disease: A systematic review","volume":"169","author":"Schweizer","year":"2025","journal-title":"J. Neurochem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.neuint.2018.10.004","article-title":"Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson\u2019s disease","volume":"121","author":"Lenda","year":"2018","journal-title":"Neurochem. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pbb.2009.09.018","article-title":"A novel 5-HT(2A) receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: Approaching early-onset antidepressants","volume":"94","author":"Pandey","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nbd.2010.01.012","article-title":"Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson\u2019s disease","volume":"38","author":"Navailles","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.neuint.2013.09.021","article-title":"Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA","volume":"63","author":"Czarnecka","year":"2013","journal-title":"Neurochem. Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.brainres.2013.10.011","article-title":"Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: The effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine","volume":"1541","author":"Czarnecka","year":"2013","journal-title":"Brain Res."},{"key":"ref_48","unstructured":"Paxinos, G., and Watson, C. (2007). The Rat Brain, Elsevier. [6th ed.]."},{"key":"ref_49","unstructured":"Paxinos, G., and Watson, C. (1986). The Rat Brain in Stereotaxic Coordinates, Academic Press."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF02244188","article-title":"An animal model of anhedonia: Attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress","volume":"104","author":"Papp","year":"1991","journal-title":"Psychopharmacology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00213-006-0630-x","article-title":"Evaluation of reward processes in an animal model of depression","volume":"190","author":"Slattery","year":"2007","journal-title":"Psychopharmacology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.brainres.2004.02.044","article-title":"Effect of 1,2,3,4-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and of [3H]GBR12,935 to dopamine transporter in the nigrostriatal, dopaminergic system","volume":"1009","author":"Wardas","year":"2004","journal-title":"Brain Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neuroscience.2015.11.049","article-title":"Adaptive down-regulation of the serotonin transporter in the 6-hydroxydopamine-induced rat model of preclinical stages of Parkinson\u2019s disease and after chronic pramipexole treatment","volume":"314","author":"Wardas","year":"2016","journal-title":"Neuroscience"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0197-0186(00)00043-7","article-title":"Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: An autoradiographic study","volume":"38","author":"Hebert","year":"2001","journal-title":"Neurochem. Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2008.04.014","article-title":"Ex vivo assessment of binding site occupancy of monoamine reuptake inhibitors: Methodology and biological significance","volume":"55","author":"Lengyel","year":"2008","journal-title":"Neuropharmacology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1007\/s00415-010-5728-8","article-title":"Pharmacokinetics of levodopa","volume":"257","author":"Contin","year":"2010","journal-title":"J. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","article-title":"Tricyclic antidepressant pharmacology and therapeutic drug interactions updated","volume":"151","author":"Gillman","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrn3027","article-title":"Neural mechanisms of the cognitive model of depression","volume":"12","author":"Disner","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrd3628","article-title":"Cognitive dysfunction in psychiatric disorders: Characteristics, causes and the quest for improved therapy","volume":"11","author":"Millan","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-8993(94)91511-3","article-title":"Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase","volume":"667","author":"Arai","year":"1994","journal-title":"Brain Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0304-3940(95)11817-G","article-title":"L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: A double-labeling immunofluorescence study","volume":"195","author":"Arai","year":"1995","journal-title":"Neurosci. Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pneurobio.2016.07.002","article-title":"Expanding the repertoire of L-DOPA\u2019s actions: A comprehensive review of its functional neurochemistry","volume":"151","author":"Millan","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/mds.21029","article-title":"Effects of Levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson\u2019s disease","volume":"21","author":"Funkiewiez","year":"2006","journal-title":"Mov. Disord."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1212\/WNL.50.5.1327","article-title":"Levodopa improves motor function without impairing cognition in mild nondemented Parkinson\u2019s disease patients","volume":"50","author":"Growdon","year":"1998","journal-title":"Neurology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1176\/jnp.2006.18.3.397","article-title":"Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson\u2019s disease","volume":"18","author":"Witt","year":"2006","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/jnnp.36.6.925","article-title":"Does levodopa alter depression and psychopathology in Parkinsonism patients?","volume":"36","author":"Marsh","year":"1973","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jns.2009.07.026","article-title":"Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment","volume":"287","author":"Kim","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Hanganu, A., Degroot, C., Monchi, O., Bedetti, C., Mejia-Constain, B., Lafontaine, A.L., Chouinard, S., and Bruneau, M.A. (2014). Influence of depressive symptoms on dopaminergic treatment of Parkinson\u2019s disease. Front. Neurol., 5.","DOI":"10.3389\/fneur.2014.00188"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Liggins, J., Pihl, R.O., Benkelfat, C., and Leyton, M. (2012). The dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0028370"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"Movement Disorder Society Evidence-Based Medicine Committee 2018. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1023\/A:1006986824213","article-title":"Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding","volume":"19","author":"Hyttel","year":"1999","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson\u2019s disease: A source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_73","first-page":"387","article-title":"Serotonin and 5-hydroxyindoleacetic acid in discrete areas of the brainstem of suicide victims and control patients","volume":"11","author":"Lloyd","year":"1974","journal-title":"Adv. Biochem. Psychopharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF01663627","article-title":"Biochemical post-mortem findings in depressed patients","volume":"37","author":"Birkmayer","year":"1975","journal-title":"J. Neural. Transm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/archpsyc.1981.01780310031002","article-title":"Monoamine metabolites in CSF and suicidal behavior","volume":"38","author":"Asberg","year":"1981","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_76","first-page":"163","article-title":"The \u201cserotonin hypothesis\u201d for depression in Parkinson\u2019s disease","volume":"53","author":"Mayeux","year":"1990","journal-title":"Adv. Neurol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/BF00314109","article-title":"Depression and Parkinson\u2019s disease: Possible role of serotonergic mechanisms","volume":"234","author":"Mrsulja","year":"1987","journal-title":"J. Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cpt1978233303","article-title":"Nortriptyline in depressed patients with high plasma levels. II","volume":"23","author":"Braithwaite","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/BF00436164","article-title":"The demethylation of amitriptyline: A cross-over study of steady-state plasma levels of amitriptyline and nortriptyline in depressed patients","volume":"80","author":"Burch","year":"1983","journal-title":"Psychopharmacology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"9986180","DOI":"10.1155\/nri\/9986180","article-title":"Synergistic effects of levodopa, benserazide, and nortriptyline on behavioral impairments and brain pathology in an experimental rat model of Parkinson\u2019s disease","volume":"2026","author":"Ezzedin","year":"2026","journal-title":"Neurol. Res. Int."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-199403001-00004","article-title":"Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)","volume":"9","author":"Hyttel","year":"1994","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0896-6273(95)90304-6","article-title":"Cellular basis of working memory","volume":"14","year":"1995","journal-title":"Neuron"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1037\/a0023165","article-title":"Molecular modulation of prefrontal cortex: Rational development of treatments for psychiatric disorders","volume":"125","author":"Gamo","year":"2011","journal-title":"Behav. Neurosci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nn1846","article-title":"Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory","volume":"10","author":"Vijayraghavan","year":"2007","journal-title":"Nat. Neurosci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev.ps.40.020189.001203","article-title":"Brain dopamine and reward","volume":"40","author":"Wise","year":"1989","journal-title":"Annu. Rev. Psychol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0301-0082(02)00011-4","article-title":"Dopamine and the regulation of cognition and attention","volume":"67","author":"Nieoullon","year":"2002","journal-title":"Prog. Neurobiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/1073858408317009","article-title":"Role of dopamine in the motivational and cognitive control of behavior","volume":"14","author":"Cools","year":"2008","journal-title":"Neuroscientist"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0165-0173(99)00045-4","article-title":"D1 receptors in prefrontal cells and circuits","volume":"31","author":"Muly","year":"2000","journal-title":"Brain Res. Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1523\/JNEUROSCI.18-07-02697.1998","article-title":"Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter","volume":"18","author":"Sesack","year":"1998","journal-title":"J. Neurosci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cne.903590211","article-title":"Dopamine transporter immunoreactivity in rat brain","volume":"359","author":"Freed","year":"1995","journal-title":"J. Comp. Neurol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/cne.10898","article-title":"Ultrastructural localization of the norepinephrine transporter in superficial and deep layers of the rat prelimbic prefrontal cortex and its spatial relationship to probable dopamine terminals","volume":"466","author":"Miner","year":"2003","journal-title":"J. Comp. Neurol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1471-4159.1990.tb04599.x","article-title":"Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: Evidence that dopamine is taken up in vivo by noradrenergic terminals","volume":"55","author":"Carboni","year":"1990","journal-title":"J. Neurochem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1471-4159.2005.03556.x","article-title":"Cumulative effect of norepinephrine and dopamine carrier blockade on extracellular dopamine increase in the nucleus accumbens shell, bed nucleus of stria terminalis and prefrontal cortex","volume":"96","author":"Carboni","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1471-4159.1994.63010195.x","article-title":"Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats","volume":"63","author":"Pozzi","year":"1994","journal-title":"J. Neurochem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1471-4159.1995.65010111.x","article-title":"Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex","volume":"65","author":"Gresch","year":"1995","journal-title":"J. Neurochem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1523\/JNEUROSCI.22-02-00389.2002","article-title":"Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: Evidence from knockout mouse lines","volume":"22","author":"Moron","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1021\/cn400046e","article-title":"Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain","volume":"4","author":"Navailles","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/cns.12275","article-title":"Noradrenergic terminals regulate L-DOPA-derived dopamine extracellular levels in a region-dependent manner in Parkinsonian rats","volume":"20","author":"Navailles","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-psych-010213-115159","article-title":"The nucleus accumbens: An interface between cognition, emotion, and action","volume":"66","author":"Floresco","year":"2015","journal-title":"Ann. Rev. Psychol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1021\/acschemneuro.4c00115","article-title":"Dopamine release dynamics in the nucleus accumbens are modulated by the timing of electrical stimulation pulses when applied to the medial forebrain bundle and medial prefrontal cortex","volume":"15","author":"Hamilton","year":"2024","journal-title":"ACS Chem. Neurosci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/(SICI)1098-2396(199711)27:3<230::AID-SYN8>3.0.CO;2-E","article-title":"Distribution of dopamine beta-hydroxylase-like immunoreactive fibers within the shell subregion of the nucleus accumbens","volume":"27","author":"Berridge","year":"1997","journal-title":"Synapse"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0006-8993(98)00672-6","article-title":"Origin of noradrenergic afferents to the shell subregion of the nucleus accumbens: Anterograde and retrograde tract-tracing studies in the rat","volume":"806","author":"Delfs","year":"1998","journal-title":"Brain Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0006-8993(79)90056-8","article-title":"Biochemical evidence for a transmitter role of dopamine in the rat hippocamus","volume":"165","author":"Bischoff","year":"1979","journal-title":"Brain Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0006-8993(94)90512-6","article-title":"Mesolimbic dopaminergic neurons innervating the hippocampal formation in the rat: A combined retrograde tracing and immunohistochemical study","volume":"668","author":"Gasbarri","year":"1994","journal-title":"Brain Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0306-4522(85)90275-1","article-title":"Morphological evidence for a dopaminergic terminal field in the hippocampal formation of young and adult rat","volume":"14","author":"Verney","year":"1985","journal-title":"Neuroscience"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Weerasinghe-Mudiyanselage, P.D.E., Ang, M.J., Kang, S., Kim, J.S., and Moon, C. (2022). Structural plasticity of the hippocampus in neurodegenerative diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063349"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.5213\/inj.2244252.126","article-title":"Changes in the neuronal architecture of the hippocampus in a 6-hydroxydopamine-lesioned rat model of Parkinson Disease","volume":"26","author":"Kim","year":"2022","journal-title":"Int. Neurourol. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/brain\/aws101","article-title":"Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson\u2019s disease","volume":"135","author":"Costa","year":"2012","journal-title":"Brain"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1474-4422(13)70118-2","article-title":"New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson\u2019s disease","volume":"12","author":"Calabresi","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01253106","article-title":"Autoradiographic localization of dopamine uptake sites in the rat brain with 3H-GBR 12935","volume":"87","author":"Mennicken","year":"1992","journal-title":"J. Neural. Transm."},{"key":"ref_111","first-page":"531","article-title":"Dopamine in the hippocampus is cleared by the norepinephrine transporter","volume":"15","author":"Borgkvist","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0022-3565(25)11249-4","article-title":"[3H]Nisoxetine: A radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding","volume":"260","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1046\/j.1471-4159.1995.64062792.x","article-title":"Comparison of (R)-[3H] tomoxetine and (R\/S)-[3H] nisoxetine binding in rat brain","volume":"64","author":"Gehlert","year":"1995","journal-title":"J. Neurochem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/(SICI)1096-9861(20000501)420:2<211::AID-CNE5>3.0.CO;2-3","article-title":"Immunolocalization of the cocaine- and antidepressant-sensitive 1-norepinephrine transporter","volume":"420","author":"Schroeter","year":"2000","journal-title":"J. Comp. Neurol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1749-6632.1998.tb10192.x","article-title":"Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission","volume":"861","author":"Blier","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"10494","DOI":"10.1523\/JNEUROSCI.19-23-10494.1999","article-title":"Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level","volume":"19","author":"Benmansour","year":"1999","journal-title":"J. Neurosci."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1523\/JNEUROSCI.22-15-06766.2002","article-title":"Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter","volume":"22","author":"Benmansour","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1096\/fj.07-095471","article-title":"Antidepressant-induced internalization of the serotonin transporter in serotonergic neurons","volume":"22","author":"Lau","year":"2008","journal-title":"FASEB J."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/5\/743\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:28:18Z","timestamp":1779510498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/5\/743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":118,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["biom16050743"],"URL":"https:\/\/doi.org\/10.3390\/biom16050743","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]}}}